This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Type of economic evaluation
Cost-effectiveness analysis
Study objective
The objective was to assess the impact of the rate of spontaneous resolution of congenital nasolacrimal duct obstruction on the relative cost-effectiveness of deferred nasolacrimal duct probing in a surgical facility, compared with immediate office-based surgical probing, in infants.
Interventions
Immediate office-based probing surgery aimed to clear the nasolacrimal duct blockage, in the physician's office, using topical anaesthesia. This was compared with delayed facility-based probing surgery, where surgery was delayed for six months, to allow spontaneous resolution; if this did not occur, surgery was undertaken in the hospital out-patient department, using general anaesthesia.
Location/setting
USA/primary and secondary care.
Methods

Analytical approach:
The authors used a decision-tree model to combine the cost and effectiveness data from a range of sources, including data on spontaneous resolution. The model evaluated infants aged six to nine months. The time horizon was until the age of 18 months. The authors stated that the perspective was that of the health care insurer.
Effectiveness data:
The evidence came from a range of sources including unpublished data on patients who took part in a published study by the Pediatric Eye Disease Investigator Group (PEDIG), a prospective observational study, and expert opinion. The main clinical parameters were the rate of spontaneous resolution and treatment success, which was defined as the absence of: epiphora (watery eye), increased tear lake, and mucus discharge.
Monetary benefit and utility valuations:
Not relevant.
Measure of benefit:
The measure of benefit was the cost per additional treatment success at 18 months old. The months of symptoms avoided were reported.
